Adam Stone, Perceptive Advisors

Per­cep­tive hits the pric­ing sweet spot on its lat­est SPAC, kick­start­ing the search for next for­ev­er part­ner

If you can say one thing about big-name biotech in­vestor Per­cep­tive Ad­vi­sors, it’s this: It knows where its pock­et is.

Af­ter pric­ing four sep­a­rate SPACs — all un­der the “Arya” moniker — right around the $130 mil­lion mark for their pub­lic of­fer­ings, Per­cep­tive is back again with the launch of its fifth fund, al­so priced in the sweet spot at $130 mil­lion.

Joseph Edel­man

Arya V, as it is known, will be chaired by Per­cep­tive CEO Joseph Edel­man with Adam Stone helm­ing the ship and Michael Alt­man, a man­ag­ing di­rec­tor at Per­cep­tive, han­dling fi­nance. The SPAC will tar­get North Amer­i­can and Eu­ro­pean life sci­ences and med­ical tech­nol­o­gy com­pa­nies in the $300 mil­lion to $500 mil­lion range with the po­ten­tial for $1 bil­lion or more in mar­ket cap, Per­cep­tive said in a re­lease.

Arya V will join the Nas­daq un­der the tick­er $ARYE with shares priced at $10. In to­tal, 14.95 mil­lion shares are be­ing reg­is­tered with the SEC, ac­cord­ing to the S-1 doc­u­ment. Un­der­writ­ers have a 45-day op­tion to pur­chase an ad­di­tion­al 1.95 mil­lion shares.

Per­cep­tive is, of course, no stranger to blank-check com­pa­nies, hav­ing tak­en four pre­vi­ous it­er­a­tions of ARYA on­to Nas­daq, most re­cent­ly in Feb­ru­ary. That month, Arya IV priced at $130 mil­lion and has yet to find its for­ev­er part­ner. Mean­while, the pre­vi­ous it­er­a­tion, Arya III, re­verse merged with Nau­tilus Biotech­nol­o­gy in Feb­ru­ary in a deal worth $350 mil­lion with the SPAC’s trust and PIPE fund­ing in­clud­ed.

Michael Alt­man

The orig­i­nal Arya signed its own pact with Im­mat­ics Biotech­nolo­gies in March 2020. That first Arya out­fit went pub­lic in 2018, but didn’t find a part­ner un­til two years lat­er, when it helped Im­mat­ics CEO Harpreet Singh ad­vance work on cell ther­a­pies to go af­ter sol­id tu­mors. Arya II, mean­while, reached a deal with Tony Coles’ Cerev­el back in Ju­ly as part of a deal val­ued at $445 mil­lion.

In Ju­ly, Arya II land­ed with Cerev­el, the Pfiz­er spin­out, to ad­vance work in Parkin­son’s and oth­er neu­ro­log­i­cal dis­eases. It land­ed a big $350 mil­lion in­vest­ment from Bain Cap­i­tal, short­ly af­ter the com­pa­ny ma­neu­vered its way through trou­bled times af­ter it closed its en­tire neu­ro­science di­vi­sion.

SPACs have start­ed mak­ing up more and more of the mar­ket, ac­count­ing for on­ly 3% of the IPO mar­ket in 2014 but swelling to more than 35% last year.

What Will it Take to Re­al­ize the Promise and Po­ten­tial of Im­mune Cell Ther­a­pies?

What does it take to get to the finish line with a new cancer therapy – fast? With approvals in place and hundreds of immune cell therapy candidates in the pipeline, the global industry is poised to create a fundamental shift in cancer treatments towards precision medicine. At the same time, unique challenges associated with cell and process complexity present manufacturing bottlenecks that delay speed to market and heighten cost of goods sold (COGS) — these hurdles must be overcome to make precision treatments an option for every cancer patient. This series of articles highlights some of the key manufacturing challenges associated with the production of cell-based cancer therapies as well as the solutions needed to transcend them. Automation, process knowledge, scalability, and assured supply of high-quality starting material and reagents are all critical to realizing the full potential of CAR-based therapies and sustaining the momentum achieved in recent years. The articles will highlight leading-edge technologies that incorporate these features to integrate across workflows, accelerate timelines and reduce COGS – along with how these approaches are enabling the biopharmaceutical industry to cross the finish line faster with new treatment options for patients in need.

The biggest ques­tions fac­ing gene ther­a­py, the XLMTM com­mu­ni­ty, and Astel­las af­ter fourth pa­tient death

After three patients died last year in an Astellas gene therapy trial, the company halted the study and began figuring out how to safely get the program back on track. They would, executives eventually explained, cut the dose by more than half and institute a battery of other measures to try to prevent the same thing from happening again.

Then tragically, Astellas announced this week that the first patient to receive the new regimen had died, just weeks after administration.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Amgen VP of R&D David Reese

Am­gen rolls out da­ta for KRAS in­hibitor com­bo study in col­orec­tal can­cer, hop­ing to move on from ug­ly ear­ly re­sults

With the first win for its KRAS inhibitor sotorasib in hand, Amgen is pushing ahead with an aggressive clinical plan to capitalize on its first-to-market standing. The drugmaker thinks combinations — in-house or otherwise — could offer a path forward, and one early readout from that strategy is bearing fruit.

A combination of Amgen’s sotorasib and its EGFR inhibitor Vectibix posted an overall response rate of 27% in 26 patients with advanced colorectal cancer (CRC) with the KRAS-G12C mutation, according to data from the larger Phase Ib/II CODEBREAK 101 study set to present at this weekend’s virtual ESMO Congress.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.

Dan O'Day, Gilead CEO (Jim Watson/AFP via Getty Images)

Eu­ro­pean study finds that Gilead­'s Covid-19 an­tivi­ral remde­sivir shows no clin­i­cal ben­e­fit

Gilead’s remdesivir — or Veklury, as it’s marketed in the US — raked in around $2.8 billion last year as the only FDA-approved antiviral to treat Covid-19. But new data from a European study suggest the drug, which has been given to about half of hospitalized Covid patients in the country, has no actual benefit.

The open-label DisCoVeRy trial enrolled Covid-19 patients across 48 sites in Europe to test a handful of treatments, including remdesivir, lopinavir–ritonavir, lopinavir–ritonavir and interferon beta-1a, and hydroxychloroquine. To participate, patients had to show symptoms for seven days and require oxygen support. A total of 429 patients were randomized to receive remdesivir plus standard of care, while 428 were assigned to standard of care alone.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.

Gri­fols drops $1B on Ger­man hold­ing com­pa­ny in con­tin­ued plas­ma push

One Spanish biotech is beefing up its plasma therapy operations, and on Friday, it announced that it’s doing so in a billion-dollar deal.

Grifols is now the largest shareholder of Biotest, a company valued at more than $1.8 billion. By teaming up, the two will try to increase the number of plasma therapies available and increase patient access around the world, Grifols said in a press release.

The company did so by acquiring holding company Tiancheng Pharmaceutical, the Germany-based owner of nearly 90% of Biotest shares, for nearly $1.27 billion. Grifols now owns nearly 90% of Biotest voting rights and almost 45% of the total share capital of Biotest.

Covid-19 roundup: FDA re­veals boost­er ad­comm ques­tion; Eli Lil­ly's an­ti­body cock­tail cleared for pre­ven­tion

The FDA released briefing documents this week from the agency and Pfizer each outlining their arguments for today’s Covid-19 booster shot adcomm, but one thing conspicuously missing was the question on which panel members would be voting. But late Thursday night, regulators published that question.

Adcomm members will be asked whether or not the safety and efficacy data from Pfizer/BioNTech’s original Phase III study “support approval” of a booster shot at least six months after the second dose in individuals older than 16. The question notably excludes the real-world data from Israel and other analyses that Pfizer and the Biden administration had said would be a centerpiece of their arguments for boosters.

A Pfiz­er part­ner wel­comes ex-ADC Ther­a­peu­tics CMO Jay Fein­gold to the team; Amid tough sled­ding, Im­muno­vant choos­es Eli Lil­ly alum as CFO

→ Last week we told you about the CMO revolving door at ADC Therapeutics, as Joseph Camardo replaced the departing Jay Feingold. The next opportunity for Feingold in the CMO slot has opened up at antibody-drug conjugate and mAb developer Pyxis Oncology, which has added several new execs and scientific advisory board members in recent months, including ex-Immunovant CFO Pamela Yanchik Connealy. Before his tenure at ADC, Feingold was Daiichi Sankyo’s VP of US medical affairs and chairman of the Global Medical Affairs Oversight Committee. Within weeks in March, Pyxis struck a licensing deal with Pfizer for two of its ADCs and raked in $152 million from a Series B round.

Wen Wang, IASO CEO

Chi­nese CAR-T play­er books a megaround to dri­ve bustling cell ther­a­py port­fo­lio through the clin­ic

China has quickly emerged as a major driver of oncology R&D in recent years, particularly in cell therapies where the potential for cheaper development has investors drooling. Now, one player, with a handful of early data, is swimming in a new round of investor cash.

IASO Bio has closed a $108 million Series C that the Chinese and California-based biotech said it will use to advance its slate of cell therapy lead programs, while also propping up a roster of next-gen allogeneic cell therapies for the future, according to a release.

Multiple antibiotic resistant Pseudomonas aeruginosa bacterium

A new way to in­fil­trate (and de­stroy) some of the dead­liest drug-re­sis­tant bugs

About four years ago, Ruben Tommasi, the gregarious scientific chief of antibiotics startup Entasis, walked into a meeting with his top chemist and top biologist to chew over another batch of unchanging results.

“It felt like we were running the same experiment over and over,” Tommasi told Endpoints News. “We had all sort of come to that point in time where we felt like we were banging our heads against the wall.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.